About: Clinical predictors of donor antibody titer and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clinical predictors of donor antibody titer and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Clinical predictors of donor antibody titer and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial
Creator	Zheng, Nai-Ying Ba, Wilson, Patrick Beavis, Kathleen Alverdy, John Ba, Dustin Ba, Haley Ba, Mari Bs, Cindy Christensen, Chancey Di Sabato, Diego Do, Madan Donington, Jessica Durkin-Celauro, Amy Ferguson, Mark Fung, John Giurcanu Phd, Mihai Guthmiller, Jenna Hee, Won Keskey, Robert Kress, John Lucia, Maria Ma, Maud Madariaga, L Matthews, Jeffrey Matushek, Scott Meltzer, David Mph, M Mph, Oh Prochaska, Micah Schrantz, Stephen Shanmugarajah, Kumaran Stovicek, Olivia Trockman Pa-C, Laura Utset Ba, Henry Vigneswaran, Janani Wang, Jiaolong Wool, Geoffrey
Source	MedRxiv
abstract	Background: Convalescent plasma therapy for COVID-19 relies on the transfer of anti-viral antibody from donors to recipients via plasma transfusion. The relationship between clinical characteristics and antibody response to COVID-19 is not well defined. We investigated predictors of convalescent antibody production and quantified recipient antibody response in a convalescent plasma therapy clinical trial. Methods: Multivariable analysis of clinical and serological parameters in 103 confirmed COVID-19 convalescent plasma donors 28 days or more following symptom resolution was performed. Mixed effects regression models with piecewise linear trends were used to characterize serial antibody responses in 10 convalescent plasma recipients with severe COVID-19. Results: Mean symptom duration of plasma donors was 11.9 and 7.8% (8/103) had been hospitalized. Antibody titers ranged from 0 to 1:3,892 (anti-receptor binding domain (RBD)) and 0 to 1:3,289 (anti-spike). Multivariable analysis demonstrated that higher anti-RBD and anti-spike titer were associated with increased age, hospitalization for COVID-19, fever, and absence of myalgia (all p<0.05). Fatigue was significantly associated with anti-RBD (p=0.03) but not anti-spike antibody titer (p=0.11). In pairwise comparison among ABO blood types, AB donors had higher anti-RBD titer than O negative donors (p=0.048) and higher anti-spike titer than O negative (p=0.015) or O positive (p=0.037) donors. Eight of the ten recipients were discharged, one remains on ECMO and one died on ECMO. No toxicity was associated with plasma transfusion. After excluding two ECMO patients and adjusting for donor antibody titer, recipient anti-RBD antibody titer increased on average 31% per day during the first three days post-transfusion (p=0.01) and anti-spike antibody titer by 40.3% (p=0.02). Conclusion: Advanced age, fever, absence of myalgia, fatigue, blood type and hospitalization were associated with higher convalescent antibody titer to COVID-19. Despite variability in donor titer, 80% of convalescent plasma recipients showed significant increase in antibody levels post-transfusion. A more complete understanding of the dose-response effect of plasma transfusion among COVID-19 patients is needed to determine the clinical efficacy of this therapy.
has issue date	2020-06-23(xsd:dateTime)
bibo:doi	10.1101/2020.06.21.20132944
has license	medrxiv
sha1sum (hex)	acbeb8ea826f518dd4ed74096b8bb0cb6bdf8280
schema:url	https://doi.org/10.1101/2020.06.21.20132944
resource representing a document's title	Clinical predictors of donor antibody titer and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial
resource representing a document's body	covid:acbeb8ea826f518dd4ed74096b8bb0cb6bdf8280#body_text
is schema:about of	named entity 'quantified' named entity 'plasma' named entity 'ANTIBODY RESPONSE' named entity 'CLINICAL TRIAL' named entity 'RESPONSE TO' named entity 'anti-viral' named entity 'plasma' named entity 'antibody' named entity 'therapy' named entity 'convalescent' named entity 'antibody' named entity 'convalescent plasma therapy' named entity 'clinical trial' named entity 'clinical characteristics' named entity 'COVID' named entity 'correlation' named entity 'Leukocyte' named entity 'Blood Bank' named entity 'epitope' named entity 'asthma' named entity 'antibody' named entity 'symptom' named entity 'antibody' named entity 'SARS-CoV2' named entity 'chi-squared test' named entity 'COVID-19' named entity 'high-risk' named entity 'autoimmune disease' named entity 'virus' named entity 'antibody' named entity 'titer' named entity 'antibody titer' named entity 'New York City' named entity 'convalescent plasma therapy' named entity 'ECMO' named entity 'transfusion' named entity 'transfusion' named entity 'blood type' named entity 'severe or life-threatening' named entity 'blood donation' named entity 'convalescent plasma' named entity 'fever' named entity 'preprint' named entity 'Data analysis' named entity 'University of Chicago Medicine' named entity 'dyspnea' named entity 'ECMO' named entity 'Blood Donation'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software